Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

NCT07314216 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Carcinoma)
Stage III
EGFR Uncommon Mutations

Interventions

DRUG: Firmonertinib
RADIATION: Definitive Thoracic Radiotherapy

Sponsor

Hunan Cancer Hospital